New drug cocktail aims to wipe out lingering leukemia

NCT ID NCT07264010

Not yet recruiting Disease control Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two oral drugs, sorafenib and venetoclax, can eliminate leftover leukemia cells in people with acute myeloid leukemia (AML) who still have measurable residual disease (MRD) after initial treatment. About 87 participants will receive the drugs for 28-day cycles. The main goal is to see if the treatment reduces MRD levels by at least 90% after three cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sorafenib and venetoclax (two drugs taken by mouth)
What this could lead to: If it works, this combination could help eliminate leftover leukemia cells that standard treatment missed, potentially lowering the chance of relapse.
What could go wrong: This is an early-to-mid stage trial with only 87 people and no comparison group, so results may not apply broadly. Both drugs can cause serious side effects like liver problems or low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloblastic leukemia with maturation acute myeloid leukemia Neoplasm, Residual

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKAEMIA (AML) MEASURABLE RESIDUAL DISEASE (MRD)

More trials for these conditions

Other studies related to the condition(s) this trial covers.